Bring it on! The FDA has approved elotuzumab (Empliciti) for use in relapsed multiple myeloma patients; the third new drug approval in three weeks!
Earlier this week, Danny Parker posted some compelling evidence that a drug commonly used to help control blood sugar in diabetics, metformin, may possess significant anti-myeloma properties. But could it work even better when combined with other drugs?
Tuesday night I was part of a panel that questioned myeloma T cell therapy pioneer, Dr. Ivan Borrello of Johns Hopkins in Baltimore. The hour shed light on how and why researchers are so hopeful about the potential of T cell immunotherapy.
I had an opportunity to interview several Takeda Pharmaceutical team members about the company’s new oral, proteasome inhibitor, Ninlaro (ixazomib), yesterday afternoon.
Following the news that not one but two new myeloma therapies are newly FDA approved, is it possible that the diabetes drug, meformin, could be a third? Before I post the fourth installment of Danny Parker’s series, I wanted to update everyone about how I’m holding up.
I don’t think I’ve ever slept as much as I did this weekend. Coming off my first pomalidomide/dex maintenance cycle, I hit the wall. If I didn’t know better I’d say my GI issues are improving. Time will tell. It’s been two steps forward, one back.
By most accounts, ixazomib (trade name, Ninlaro) should work as well or even better than Velcade. Preliminary reports are hopeful that adverse side effects may be fewer and more tolerable, too. “But storm clouds on the horizon?”
The FDA approved Takeda’s oral proteasome inhibitor, ixazomib, late this morning. First daratumumab on on Monday and now ixazomib today.
Could it be that newly diagnosed myeloma patients might benefit and live longer if prescribed the diabetes drug, metformin? Possibly relapsed patients, too? Here is the second installment of Danny Parker’s series:
According to officials at the FDA, yesterday “the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.”
More good news about Mike Barron and his successful run with daratumumab. Mike wants all to know that his latest cycle picks up where the last on left off: daratumumab and dex is doing the trick. “It’s like a miracle,” Mike wrote me.
I ran across this comprehensive article about the emergence of new myeloma immunotherapies on OncLive.com over the weekend. It features a who’s who of myeloma experts.
A number of you have already contributed to help CrowdCare Foundation fund a pair of cutting edge T cell trials in Germany and John Hopkins in Baltimore. THANK YOU! For those of you on-the-fence, I wanted to share some good news.
I had a chance to see myeloma patient and CrowdCare Foundation co-founder, Jenny Ahlstrom, in Boston last week. She made an impassioned plea to anyone that would listen to help her raise money to pay for two cutting edge T cell clinical trials; one in the U.S. and one in Germany.
We were all so excited! Dying myeloma patient, Stacy from Minnesota, responded miraculously to Mayo Clinic’s experimental measles vaccine therapy. Yet apparently attempts to match this early success is fleeting.
This is important. There has been a lot of contradictory data on whether long term maintenance increases overall survival (OS) enough to justify the side effects and cost. This retrospective study, done on multiple myeloma patients in Europe, seems to support it.
An important prognostic development was announced earlier this year by researchers in England. Check out this excerpt from MedPageToday’s special report, Mutations in Myeloma Predict Outcome:
Last year at ASH, everyone was anticipating FDA approval of carfilzomib (Kyrpolis) and pomalidomide (Pomalyst). It felt a lot like it does now, expecting the first two myeloma related immunotherapies, elotuzumab and daratumumab, to be approved within the next six months.
Don’t sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda’s oral proteasome inhibitor (MLN9708) at this year’s ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015.
While our brand new CrowdCare Foundation continues to raise money to help support two specific T cell therapies, the MMRF embraces a much broader mission. I’m pleased to announce that the MMRF has now tested 1000 newly diagnosed patients that have agreed to be monitored from beginning to end. Tracking their progress–through a variety of […]